Advertisement


Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease

2022 ASH Annual Meeting and Exposition

Advertisement

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this first head-to-head comparison of the two BTK inhibitors, the superior progression-free survival of zanubrutinib was observed across all major subgroups, including high-risk patients (Abstract LBA-6).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The Alpine study is a randomized phase-three trial comparing zanubrutinib to ibrutinib in relapsed/refractory CLL patients. As a reminder, ibrutinib is our first-in-class BTK inhibitor, which has been transformative for CLL therapy but has significant adverse events. Zanubrutinib is a next-generation drug, which is more specific for BTK and also maintains drug levels throughout the dosing interval, potentially allowing greater BTK occupancy. Alpine was designed to assess the efficacy and safety of zanubrutinib in comparison to ibrutinib. The population was an all-comer relapsed/refractory population with a median of one prior therapy, which was chemoimmunotherapy by and large. The randomization was stratified by age, geographic area relapsed/refractory disease, and deletion 17p or TP53 aberrancy. The findings that I presented at ASH this year demonstrated that zanubrutinib has a superior progression-free survival compared to ibrutinib in this setting with a hazard ratio of 0.65 and a two-year landmark of 79% progression-free survival for zanubrutinib versus 67% for ibrutinib, so a 12% improvement. This was seen across all subgroups of disease, but in particular, the high-risk deletion 17p/TP53 aberrant patients had a 22% improvement in their two-year landmark PFS. The median PFS with ibrutinib was reached at 36 months, but not reached with zanubrutinib. In addition to this, zanubrutinib continues to have a higher overall response rate than ibrutinib, which was actually the primary endpoint of the study, but PFS was a key secondary endpoint that we reported here. It was event-driven after 205 events. In terms of safety, zanubrutinib was also safer than ibrutinib. There were fewer drug discontinuations, fewer drug holds, fewer drug interruptions for toxicity. Perhaps most importantly, the cardiac safety was significantly improved with fewer cardiac serious adverse events. Only one drug discontinuation for a cardiac adverse event with zanubrutinib versus 14 for ibrutinib, and perhaps most notably, no cardiac death with zanubrutinib versus six with ibrutinib. In terms of other toxicities, the most common toxicity was neutropenia, which was 23% grade three or higher with zanubrutinib versus 22% with ibrutinib, so pretty comparable, although there were fewer associated infections with zanubrutinib at 9% versus 13% with ibrutinib. COVID-19 was the next most common adverse event and the most common adverse event leading to death at about 4% in zanubrutinib and 5% in ibrutinib. Hypertension was balanced between the arms. So in summary, the Alpine study demonstrated that zanubrutinib has a superior progression-free survival to ibrutinib in relapsed/refractory CLL patients and is also better tolerated with a particularly better cardiac profile, which is one of our key points we worry about with BTK inhibitors. The results of this study are potentially practice-changing, demonstrating that zanubrutinib is a new standard of care for CLL. Are there any follow-up studies you want to mention? Although this was the final analysis of progression-free survival, there will be ongoing analysis and we'll certainly be interested in more mature data as this is about 30 month follow up. We're also interested in studies that are evaluating combination of zanubrutinib and venetoclax, or zanubrutinib and other Bcl-2 inhibitors looking potentially at time limited therapy similar to what's been done with other BTK inhibitors, mostly ibrutinib to date, but also acalabrutinib.

Related Videos

Hematologic Malignancies
Genomics/Genetics

Smita Bhatia, MD, MPH: Some Clonal Mutations May Predict Therapy-Related Myeloid Neoplasms

Smita Bhatia, MD, MPH, of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discusses study findings that showed key somatic mutations in the peripheral blood stem cell product increases the risk of developing therapy-related myeloid neoplasms (Abstract 119).

Multiple Myeloma

Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).

Hematologic Malignancies
Immunotherapy

Joseph Schroers-Martin, MD, on Posttransplant Lymphoproliferative Disorders: Tumor Microenvironment Determinants of Immunotherapy Response

Joseph Schroers-Martin, MD, of Stanford University, discusses immunogenomic features reflecting divergent biology in posttransplant lymphoproliferative disorders (PTLD). These include evidence of mismatch repair defects in Epstein-Barr virus–positive PTLD, tumor microenvironment depletion, and MYC pathway enrichment in certain patients (Abstract 72).

Leukemia

Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent

Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a large, multicenter study that showed superior outcomes with 7 + 3 chemotherapy (cytarabine continuously for 7 days, along with short infusions of an anthracycline on each of the first 3 days) vs venetoclax in patients with acute myeloid leukemia (AML). In this real-world data set, the 7 + 3 cohort outperformed historical benchmarks in overall survival and early mortality, perhaps reflecting improved later lines of therapy and patient selection. Prospective studies (such as NCT04801797) must confirm the superiority of intensive chemotherapy (Abstract 426).

 

Multiple Myeloma
Immunotherapy

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).

Advertisement

Advertisement




Advertisement